This site is intended for healthcare professionals

3D render of the human body showing lung cancer tumours highlighted in red and orange

Non-small Cell Lung Cancer

Last updated: 3rd Sep 2024

Non-small cell lung cancer (NSCLC) is a frequently diagnosed cancer type and a leading cause of cancer-related death.¹

Treatments for NSCLC include surgery, chemotherapy, radiation therapy, and targeted therapy.² The treatment landscape of resectable NSCLC has been enhanced for patients with NSCLC following the approval of systemic treatments, such as atezolizumab, osimertinib, pembrolizumab, and nivolumab combined with chemotherapy.^3,4

Many clinical challenges persist in the face of these advances. For example, factors such as abnormal antigen presentation, functional gene mutation, and the tumour microenvironment can contribute to treatment resistance. The mechanisms of acquired resistance to these therapies are under investigation.³

3D render of the human body showing lung cancer tumours highlighted in red and orange

Independent, grant-supported education for non-small cell lung cancer

Industry-sponsored resources

Doctor holding patients hand in consultation

Doctor holding patients hand in consultation

Supportive care in oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Related news and insights

Blue test tubes arranged in a line, disappearing into the background

NICE (UK) positive for Alecensa (alectinib) for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) .- Roche

1 mins

Positive results from the pivotal Phase III MK-3475A-D77 trial for subcutaneous pembrolizumab in NSCLC

Merck Inc., (known as MSD outside of the United States and Canada,) announced positive topline results from the pivotal Phase III MK-3475A-D77 trial

2 min

CHMP recommends Rybrevant (amivantamab) plus Lazcluze (lazertinib) for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the Marketing Authorisation (MA)for Lazcluze (lazertinib), in combination with Rybrevant (amivantamab), for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R (L858R) substitution mutations

2 min

See all news

Related Journal Articles

Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective

1 mins

Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial

1 mins

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial

2 mins

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

1 mins

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial

2 mins

NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis

1 mins

Targeted therapies for cancer

1 mins

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

1 mins

P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC

1 mins

MA26.06 Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative

1 mins

Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update

1 mins

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update

1 mins

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing

1 mins

Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices

1 mins

Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors

1 mins

The biology and management of non-small cell lung cancer

1 mins

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

1 mins

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

1 mins

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

1 mins

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)

1 mins

Lung microbiome alterations in NSCLC patients

1 mins

The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

1 mins

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

1 mins

Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab

1 mins

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

1 mins

Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era

1 mins

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

1 mins

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

1 mins

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

1 mins

Development and Evaluation of a Real-World Outcomes-Based Tool to Support Informed Clinical Decision Making in the Palliative Treatment of Patients With Metastatic NSCLC

1 mins

Related Guidelines

Guidelines

Screening for lung cancer: 2023 guideline update from the American Cancer Society

Our objective was to update the American Cancer Society (ACS) 2013 lung cancer screening (LCS) guideline for adults at high risk for lung cancer. The guideline is intended to provide guidance for screening to health care providers and their patients who are at high risk for lung cancer due to a history of smoking.

1 mins

Definitive and Adjuvant Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline

The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on external-beam radiotherapy for patients with locally advanced non–small-cell lung cancer (NSCLC).

1 min

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

This update [...] addresses two principal questions in the treatment of patients with completely resected non–small-cell lung cancers (NSCLCs): the overall survival benefit and role of adjuvant systemic therapy, including chemotherapy and newer targeted therapy and immunotherapy options, and adjuvant radiation therapy.

1 min

See all guidelines

Related Clinical Trials

A close up image of a microscope

A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

1 mins

A close up image of a microscope

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (PACIFIC-5)

1 mins

A close up image of a microscope

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

1 mins

A close up image of a microscope

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

1 mins

A close up image of a microscope

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART)

1 mins

A close up image of a microscope

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

2 mins

A close up image of a microscope

Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (SELECT)

1 mins

A close up image of a microscope

SAR408701 in Combination With Pembrolizumab and Pembrolizumab Alone in Patients With Non-squamous Non-small Cell Lung Cancer (NSQ NSCLC) (CARMEN-LC05)

1 mins

A close up image of a microscope

A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

1 mins

A close up image of a microscope

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

1 mins

A close up image of a microscope

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

1 mins

A close up image of a microscope

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)

1 mins

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249.
NCI, 2024. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq. Accessed May 20, 2024.
Houda I, Dickhoff C, Uyl-De Groot CA, Damhuis RAM, Reguart N, Provencio M, et al. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective. The Lancet. 2024;38:100841.
Houda I, Dickhoff C, Uyl-De Groot CA, Reguart N, Provencio M, Levy A, et al. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. The Lancet. 2024;38:100840.